Viking Therapeutics Company Profile (NASDAQ:VKTX)

About Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics logoViking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VKTX
  • CUSIP: N/A
  • Web: www.vikingtherapeutics.com
Capitalization:
  • Market Cap: $28.8 million
  • Outstanding Shares: 27,697,000
Average Prices:
  • 50 Day Moving Avg: $1.06
  • 200 Day Moving Avg: $1.25
  • 52 Week Range: $0.88 - $1.70
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.32
  • P/E Growth: -0.03
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.24 per share
  • Price / Book: 4.33
Profitability:
  • Return on Equity: -220.52%
  • Return on Assets: -118.36%
Debt:
  • Current Ratio: 1.85%
  • Quick Ratio: 1.85%
Misc:
  • Average Volume: 197,177 shs.
  • Beta: 1.09
  • Short Ratio: 1
 

Frequently Asked Questions for Viking Therapeutics (NASDAQ:VKTX)

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its earnings results on Wednesday, August, 9th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. View Viking Therapeutics' Earnings History.

When will Viking Therapeutics make its next earnings announcement?

Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Viking Therapeutics.

Where is Viking Therapeutics' stock going? Where will Viking Therapeutics' stock price be in 2017?

2 brokers have issued twelve-month target prices for Viking Therapeutics' shares. Their forecasts range from $5.00 to $7.00. On average, they anticipate Viking Therapeutics' stock price to reach $6.00 in the next year. View Analyst Ratings for Viking Therapeutics.

Who are some of Viking Therapeutics' key competitors?

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the folowing people:

  • Lawson Macartney Ph.D., Chairman of the Board
  • Brian W. Lian Ph.D., President, Chief Executive Officer, Director
  • Michael Morneau, Chief Financial Officer
  • Amy Broidrick, Senior Vice President - Corporate Development
  • Gregory S. Zante CPA, Vice President - Finance and Operations
  • Catherine Lee Kelleher M.D., Vice President - Clinical Development
  • Matthew W. Foehr, Director
  • Charles A. Rowland Jr., Director
  • Matthew Singleton, Independent Director
  • Stephen W. Webster, Independent Director

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Who owns Viking Therapeutics stock?

Viking Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.38%) and Virtu KCG Holdings LLC (0.48%). View Institutional Ownership Trends for Viking Therapeutics.

Who bought Viking Therapeutics stock? Who is buying Viking Therapeutics stock?

Viking Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC. View Insider Buying and Selling for Viking Therapeutics.

How do I buy Viking Therapeutics stock?

Shares of Viking Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of Viking Therapeutics stock can currently be purchased for approximately $1.04.


MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Viking Therapeutics (NASDAQ:VKTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (476.92% upside)

Analysts' Ratings History for Viking Therapeutics (NASDAQ:VKTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Maxim GroupSet Price TargetBuy$5.00HighView Rating Details
7/17/2017HC WainwrightReiterated RatingBuy -> Buy$5.00 -> $7.00LowView Rating Details
8/11/2016LaidlawLower Price TargetBuy$20.00 -> $10.00N/AView Rating Details
10/15/2015Feltl & Co.Reiterated RatingStrong-BuyN/AView Rating Details
(Data available from 8/23/2015 forward)

Earnings

Earnings History for Viking Therapeutics (NASDAQ:VKTX)
Earnings by Quarter for Viking Therapeutics (NASDAQ:VKTX)
Earnings History by Quarter for Viking Therapeutics (NASDAQ VKTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.19)N/AView Earnings Details
8/9/2017Q2 2017($0.19)($0.21)ViewListenView Earnings Details
3/21/2017Q4 2016($0.20)($0.18)ViewN/AView Earnings Details
11/10/2016Q316($0.21)($0.20)ViewN/AView Earnings Details
8/10/2016Q2($0.20)($0.22)ViewN/AView Earnings Details
5/10/2016Q1($0.45)($0.40)ViewN/AView Earnings Details
3/8/2016Q415($0.44)($0.56)ViewN/AView Earnings Details
11/5/2015($0.37)($0.53)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($1.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Viking Therapeutics (NASDAQ:VKTX)
2017 EPS Consensus Estimate: ($0.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.20)($0.20)($0.20)
Q3 20172($0.20)($0.19)($0.20)
Q4 20172($0.19)($0.17)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Viking Therapeutics (NASDAQ:VKTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Viking Therapeutics (NASDAQ:VKTX)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 2.79%
Insider Trades by Quarter for Viking Therapeutics (NASDAQ:VKTX)
Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)
Insider Trades by Quarter for Viking Therapeutics (NASDAQ:VKTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2016Matthew W FoehrDirectorBuy13,000$1.21$15,730.00View SEC Filing  
4/13/2016Matthew W FoehrDirectorBuy20,000$1.24$24,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Viking Therapeutics (NASDAQ:VKTX)
Latest Headlines for Viking Therapeutics (NASDAQ:VKTX)
Source:
DateHeadline
americanbankingnews.com logoZacks Investment Research Weighs in on Viking Therapeutics, Inc.'s Q3 2017 Earnings (VKTX)
www.americanbankingnews.com - August 17 at 7:46 AM
finance.yahoo.com logoVKTX: Data From Phase 2 Trial of VK5211 Expected in 4Q17
finance.yahoo.com - August 15 at 8:02 AM
americanbankingnews.com logoViking Therapeutics, Inc. (VKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - August 10 at 6:21 PM
finance.yahoo.com logoViking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 9:26 AM
prnewswire.com logoViking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 - PR Newswire (press release)
www.prnewswire.com - August 2 at 8:28 AM
finance.yahoo.com logoViking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017
finance.yahoo.com - August 2 at 8:28 AM
americanbankingnews.com logoViking Therapeutics, Inc. (VKTX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
americanbankingnews.com logo Analysts Anticipate Viking Therapeutics, Inc. (VKTX) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - July 31 at 12:28 PM
finance.yahoo.com logoCorporate News Blog - Viking Therapeutics Completes Enrollment in Phase-2 study of VK5211 in Patients Recovering from Hip Fracture
finance.yahoo.com - July 14 at 9:44 AM
streetinsider.com logoViking Therapeutics (VKTX) Completes Enrollment in Phase 2 Study of VK5211 - StreetInsider.com
www.streetinsider.com - July 13 at 11:15 AM
finance.yahoo.com logoViking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
finance.yahoo.com - July 12 at 8:56 AM
americanbankingnews.com logoZacks: Brokerages Expect Viking Therapeutics, Inc. (NASDAQ:VKTX) to Announce -$0.17 Earnings Per Share
www.americanbankingnews.com - July 7 at 9:08 AM
streetinsider.com logoViking Therapeutics (VKTX) Names Charles Rowland Jr. to Board - StreetInsider.com
www.streetinsider.com - July 7 at 2:42 AM
finance.yahoo.com logoViking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
finance.yahoo.com - July 6 at 4:38 PM
americanbankingnews.com logoForward Pharma A/S (FWP) and Viking Therapeutics (VKTX) Financial Review
www.americanbankingnews.com - July 1 at 6:20 PM
finance.yahoo.com logoVKTX Raises $4.3 Million in Gross Proceeds From Registered Direct Offering…
finance.yahoo.com - June 20 at 9:03 AM
finance.yahoo.com logoViking Therapeutics Announces $4.3 Million Registered Direct Offering
finance.yahoo.com - June 15 at 4:04 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Viking Therapeutics, Inc. (VKTX) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - June 13 at 8:20 AM
finance.yahoo.com logoVKTX: Potential of VK2809 in NASH Treatment Shown in Diet-Induced Mouse Model
finance.yahoo.com - June 8 at 1:51 AM
americanbankingnews.com logoMaxim Group Analysts Give Viking Therapeutics Inc (VKTX) a $5.00 Price Target
www.americanbankingnews.com - June 7 at 6:14 PM
streetinsider.com logoViking Therapeutics (VKTX) Announces Top Line Results from In Vivo Study of VK2809 to Treat NASH - StreetInsider.com
www.streetinsider.com - June 7 at 12:44 AM
finance.yahoo.com logoViking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
finance.yahoo.com - June 7 at 12:44 AM
seekingalpha.com logoViking Therapeutics: The Good, The Bad, And (Maybe) The Ugly - Seeking Alpha
seekingalpha.com - May 25 at 6:37 AM
americanbankingnews.com logo Analysts Anticipate Viking Therapeutics Inc (VKTX) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 16 at 4:04 PM
americanbankingnews.com logoMaxim Group Reaffirms "Buy" Rating for Viking Therapeutics Inc (VKTX)
www.americanbankingnews.com - May 13 at 11:56 PM
finance.yahoo.com logoVKTX: Multiple Data Readouts Ahead in 2017
finance.yahoo.com - May 13 at 2:44 AM
prnewswire.com logoViking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update - PR Newswire (press release)
www.prnewswire.com - May 12 at 3:57 AM
seekingalpha.com logoViking Therapeutics' (VKTX) Brian Lian on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 12 at 3:57 AM
finance.yahoo.com logoViking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 3:13 AM
americanbankingnews.com logoViking Therapeutics Inc (VKTX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 9:41 AM
finance.yahoo.com logoViking Therapeutics to Report Financial Results for First Quarter 2017 After ...
finance.yahoo.com - May 8 at 9:03 AM
americanbankingnews.com logoViking Therapeutics (VKTX) Receives News Sentiment Score of 0.31
www.americanbankingnews.com - May 4 at 12:22 PM
finance.yahoo.com logoViking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017
finance.yahoo.com - May 3 at 9:54 AM
americanbankingnews.com logoViking Therapeutics (VKTX) Earning Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - May 1 at 3:50 PM
americanbankingnews.com logoViking Therapeutics (VKTX) Receives Media Sentiment Score of -0.08
www.americanbankingnews.com - April 27 at 12:00 PM
americanbankingnews.com logoViking Therapeutics Inc (VKTX) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 26 at 12:03 AM
americanbankingnews.com logoViking Therapeutics (VKTX) Given Daily Media Impact Score of 0.31
www.americanbankingnews.com - April 24 at 10:24 AM
americanbankingnews.com logoViking Therapeutics (VKTX) Getting Very Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 1:11 PM
americanbankingnews.com logoViking Therapeutics (VKTX) Receives Media Sentiment Rating of 0.29
www.americanbankingnews.com - April 17 at 10:52 AM
americanbankingnews.com logoViking Therapeutics (VKTX) Earns Media Sentiment Rating of 0.37
www.americanbankingnews.com - April 13 at 2:30 PM
americanbankingnews.com logoViking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - March 31 at 11:53 AM
americanbankingnews.com logoBrokerages Expect Viking Therapeutics Inc (VKTX) to Announce ($0.18) EPS
www.americanbankingnews.com - March 29 at 12:20 PM
finance.yahoo.com logoViking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference
finance.yahoo.com - March 28 at 8:25 AM
americanbankingnews.com logoEquities Analysts Offer Predictions for Viking Therapeutics Inc's FY2019 Earnings (VKTX)
www.americanbankingnews.com - March 27 at 9:56 AM
americanbankingnews.com logoViking Therapeutics Inc (VKTX) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - March 27 at 9:26 AM
americanbankingnews.com logoViking Therapeutics Inc (VKTX) Given a $5.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 26 at 9:46 PM
finance.yahoo.com logoVIKING THERAPEUTICS, INC. Financials
finance.yahoo.com - March 25 at 8:12 PM
americanbankingnews.com logoViking Therapeutics Inc (VKTX) PT Set at $5.00 by Maxim Group
www.americanbankingnews.com - March 24 at 11:04 PM
finance.yahoo.com logoVKTX: Results from Phase 2 Trial of VK5211 in Hip Fracture in mid-2017
finance.yahoo.com - March 24 at 3:29 PM
americanbankingnews.com logoFeltl & Co. Comments on Viking Therapeutics Inc's Q1 2017 Earnings (VKTX)
www.americanbankingnews.com - March 24 at 8:05 AM

Social

Chart

Viking Therapeutics (VKTX) Chart for Wednesday, August, 23, 2017

This page was last updated on 8/23/2017 by MarketBeat.com Staff